This technology is an immunomodulatory peptide that alters tumor microenvironments to improve patient outcomes and survival in cancers resistant to immunotherapies.
Many types of cancer, such as pancreatic ductal adenocarcinoma (PDAC), are resistant to chemo- and immunotherapy. Immunotherapy-resistant tumors are characterized by a microenvironment enriched in regulatory T cells (Tregs), which suppress the immune system’s ability to attack the tumor and limit the effectiveness of immunotherapies. Although there is a need for strategies that sensitize these cancers to immunotherapy, systemic depletion of Tregs is not a viable solution due to side effects such as autoimmune toxicity.
This technology describes the ability of tumor internalizing (iRGD) peptides to sensitize PDAC and other cancers to immunotherapy by depleting immunosuppressive Tregs in a tumor-specific manner. This results in a localized expansion of effector CD8+ T cells, which attack the tumor without the inflammatory side effects associated with systemic Treg depletion. As such, iRGD peptides prevent tumor resistance, reduce tumor burden, and prolong survival.
This technology has been validated in a PDAC mouse model.
Patent Pending(US20240000883)
IR CU21100, CU23106
Licensing Contact: Jerry Kokoshka